BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barreiro-Alonso A, Lamas-Maceiras M, García-Díaz R, Rodríguez-Belmonte E, Yu L, Pardo M, Choudhary JS, Cerdán ME. Delineating the HMGB1 and HMGB2 interactome in prostate and ovary epithelial cells and its relationship with cancer. Oncotarget 2018;9:19050-64. [PMID: 29721183 DOI: 10.18632/oncotarget.24887] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Hardiman G, Savage SJ, Hazard ES, da Silveira WA, Morgan R, Harris A, Jefferson MS, Wilson RC, Caulder S, Ambrose L, Frey L, Wolf B, Gattoni-Celli S, Hughes Halbert C. A Systems Approach to Interrogate Gene Expression Patterns in African American Men Presenting with Clinically Localized Prostate Cancer. Cancers (Basel) 2021;13:5143. [PMID: 34680291 DOI: 10.3390/cancers13205143] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Voong CK, Goodrich JA, Kugel JF. Interactions of HMGB Proteins with the Genome and the Impact on Disease. Biomolecules 2021;11:1451. [PMID: 34680084 DOI: 10.3390/biom11101451] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
3 Cámara-Quílez M, Barreiro-Alonso A, Vizoso-Vázquez Á, Rodríguez-Belmonte E, Quindós-Varela M, Lamas-Maceiras M, Cerdán ME. The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB Proteins and Their Interacting Partners MIEN1 and NOP53 in Ovary Cancer and Drug-Response. Cancers (Basel) 2020;12:E2435. [PMID: 32867128 DOI: 10.3390/cancers12092435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Barreiro-Alonso A, Cámara-Quílez M, Salamini-Montemurri M, Lamas-Maceiras M, Vizoso-Vázquez Á, Rodríguez-Belmonte E, Quindós-Varela M, Martínez-Iglesias O, Figueroa A, Cerdán ME. Characterization of HMGB1/2 Interactome in Prostate Cancer by Yeast Two Hybrid Approach: Potential Pathobiological Implications. Cancers (Basel) 2019;11:E1729. [PMID: 31694235 DOI: 10.3390/cancers11111729] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
5 Fassi EMA, Sgrignani J, D'Agostino G, Cecchinato V, Garofalo M, Grazioso G, Uguccioni M, Cavalli A. Oxidation State Dependent Conformational Changes of HMGB1 Regulate the Formation of the CXCL12/HMGB1 Heterocomplex. Comput Struct Biotechnol J 2019;17:886-94. [PMID: 31333815 DOI: 10.1016/j.csbj.2019.06.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
6 Kumar S, Kushwaha PP, Gupta S. Emerging targets in cancer drug resistance. Cancer Drug Resist 2019;2:161-77. [PMID: 35582722 DOI: 10.20517/cdr.2018.27] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
7 Vizoso-Vázquez A, Barreiro-Alonso A, González-Siso MI, Rodríguez-Belmonte E, Lamas-Maceiras M, Cerdán ME. HMGB proteins involved in TOR signaling as general regulators of cell growth by controlling ribosome biogenesis. Curr Genet 2018;64:1205-13. [PMID: 29713761 DOI: 10.1007/s00294-018-0842-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]